DJIA 17,039.49 60.36 0.36%
NASDAQ 4,532.10 5.62 0.12%
S&P 500 1,992.37 5.86 0.29%
market minute promo

Biogen Idec (NASDAQ: BIIB)

338.65 -3.93 (-1.15%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

BIIB $338.65 -1.15%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $342.73
Previous Close $342.58
Daily Range $337.19 - $344.42
52-Week Range $203.55 - $358.89
Market Cap $80.0B
P/E Ratio 38.11
Dividend (Yield) $0.00 (0.0%)
Volume 663,651
Average Daily Volume 1,285,816
Current FY EPS $13.13

Sector

Healthcare

Industry

Drugs

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website: http://www.biogenidec.com/

News & Commentary Rss Feed

Why Biogen Idec Stock Is Firing on All Cylinders

Biogen Idec's latest earnings report is the envy of the industry with better than expected growth of its soon to be best-seller Tecfidera.

What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Anal

Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog

3 Drugs Stocks Dragging The Industry Down

6 Biotech Stocks to Buy Now With Up to 100% Upside Potential

Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog

Noteworthy ETF Outflows: IYH, AMGN, BIIB, CELG

Why Biogen Idec (BIIB) Stock Is Gaining Today

UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval

Today's Momo Momentum Stock Is Biogen Idec (BIIB)

Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog

See More BIIB News...

BIIB's Top Competitors

BIIB $338.65 (-1.15%)
Current stock: BIIB
AMGN $132.53 (-0.11%)
Current stock: AMGN
GILD $102.27 (1.47%)
Current stock: GILD
$0.00 (0.00%)
Current stock: